• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Henry Schein Announces Completion of Strategic Investment by KKR and Appointment of Dan Daniel to Board of Directors

    5/16/25 4:10:00 PM ET
    $HSIC
    $KKR
    Medical Specialities
    Health Care
    Investment Managers
    Finance
    Get the next $HSIC alert in real time by email

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced the successful completion of a $250 million strategic investment by funds affiliated with KKR, a leading global investment firm. Upon the closing of this transaction, KKR has become the holder of approximately 12% of the common shares of Henry Schein.

    In connection with the investment, William K. "Dan" Daniel, Executive Advisor to KKR and former Executive Vice President of Danaher Corporation, has officially joined Henry Schein's Board of Directors as an independent director. He joins Max Lin, Partner at KKR and leader of the firm's Health Care industry team in the Americas, who became a member of Henry Schein's Board of Directors on May 2, 2025.

    Max Lin leads the Health Care industry team within KKR, and since joining in 2005, he has overseen a number of investments in the areas of dental services and other health care providers, medical products and equipment, and health care software and information technology. Dan Daniel has over three decades of global leadership experience in industrial and health care sectors, including 14 years as Executive Vice President at Danaher, where he oversaw multiple segments and played a key role in advancing the company's culture and business system. In connection with each of their appointments, Mr. Lin was appointed to the Nominating and Governance Committee as Vice Chair; Mr. Daniel was appointed to the Compensation Committee; and each of Mr. Lin and Mr. Daniel was appointed to the Strategic Advisory Committee.

    "We are pleased to welcome Max and Dan to the Board as we embark on this exciting next chapter for Henry Schein," said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. "Their deep experience in health care, operations, and strategic growth will be invaluable as we continue executing on our BOLD+1 strategy and creating long-term value for our stakeholders."

    About Henry Schein, Inc.

    Henry Schein, Inc. (NASDAQ:HSIC) is a solutions company for health care professionals powered by a network of people and technology. With approximately 25,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.

    Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our distribution centers.

    A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories. The Company's sales reached $12.7 billion in 2024, and have grown at a compound annual rate of approximately 11.2 percent since Henry Schein became a public company in 1995.

    For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, Instagram.com/HenrySchein, LinkedIn.com/Company/HenrySchein, and @HenrySchein on X.

    About KKR

    KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR's insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR's investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE:KKR), please visit KKR's website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group's website at www.globalatlantic.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250516439220/en/

    Investors

    Ronald N. South

    Senior Vice President and Chief Financial Officer

    [email protected]

    (631) 843-5500



    Graham Stanley

    Vice President, Investor Relations and Strategic Financial Project Officer

    [email protected]

    (631) 843-5500



    Media

    Henry Schein

    Tim Vassilakos

    Executive Director, Global Corporate Communications

    [email protected]

    (516) 510-0926



    KKR

    Liidia Liuksila

    [email protected]

    Get the next $HSIC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HSIC
    $KKR

    CompanyDatePrice TargetRatingAnalyst
    Henry Schein Inc.
    $HSIC
    7/25/2025$75.00Buy → Hold
    Stifel
    KKR & Co. Inc.
    $KKR
    7/14/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    Henry Schein Inc.
    $HSIC
    7/14/2025$72.00Outperform → Neutral
    Robert W. Baird
    KKR & Co. Inc.
    $KKR
    7/9/2025$142.00Buy → Hold
    HSBC Securities
    KKR & Co. Inc.
    $KKR
    6/30/2025$150.00Overweight
    Piper Sandler
    KKR & Co. Inc.
    $KKR
    5/14/2025$150.00Equal-Weight → Overweight
    Morgan Stanley
    KKR & Co. Inc.
    $KKR
    4/15/2025$119.00Hold → Buy
    HSBC Securities
    KKR & Co. Inc.
    $KKR
    3/20/2025$150.00 → $141.00Equal Weight → Overweight
    Wells Fargo
    More analyst ratings

    $HSIC
    $KKR
    SEC Filings

    View All

    SEC Form 10-Q filed by KKR & Co. Inc.

    10-Q - KKR & Co. Inc. (0001404912) (Filer)

    8/8/25 4:43:19 PM ET
    $KKR
    Investment Managers
    Finance

    SEC Form 144 filed by KKR & Co. Inc.

    144 - KKR & Co. Inc. (0001404912) (Subject)

    8/7/25 6:30:10 PM ET
    $KKR
    Investment Managers
    Finance

    KKR & Co. Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

    8-K - KKR & Co. Inc. (0001404912) (Filer)

    8/7/25 4:37:55 PM ET
    $KKR
    Investment Managers
    Finance

    $HSIC
    $KKR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Kkr Hawaii Holdings L.P. claimed ownership of 15,263,662 shares (SEC Form 3)

    3 - HENRY SCHEIN INC (0001000228) (Issuer)

    8/15/25 9:30:38 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Chief Financial Officer Lewin Robert H gifted 2,500 shares, decreasing direct ownership by 0.21% to 1,196,726 units (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    8/15/25 8:00:32 PM ET
    $KKR
    Investment Managers
    Finance

    SEC Form 4 filed by Large owner Kkr Hawaii Aggregator L.P.

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    8/14/25 7:00:45 PM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    $KKR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Henry Schein downgraded by Stifel with a new price target

    Stifel downgraded Henry Schein from Buy to Hold and set a new price target of $75.00

    7/25/25 8:58:32 AM ET
    $HSIC
    Medical Specialities
    Health Care

    KKR downgraded by Citizens JMP

    Citizens JMP downgraded KKR from Mkt Outperform to Mkt Perform

    7/14/25 8:40:54 AM ET
    $KKR
    Investment Managers
    Finance

    Henry Schein downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Henry Schein from Outperform to Neutral and set a new price target of $72.00

    7/14/25 8:40:13 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    $KKR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    THL Announces Agreement to Acquire Headlands Research from KKR

    Strategic Partnership to Advance Site Network Expansion and Accelerate Clinical Trial Innovation THL Partners ("THL"), a premier private equity firm investing in middle market growth companies, today announced the entry into a definitive agreement to acquire Headlands Research ("Headlands" or "the Company"), a leading multinational network of clinical trial sites, from funds managed by leading global investment firm KKR. The strategic partnership between THL and Headlands will fuel Headlands' continued expansion, enhance its technology and centralized infrastructure, and further strengthen its ability to deliver high-quality, diverse clinical trial data for pharmaceutical and biotech spon

    8/14/25 9:00:00 AM ET
    $KKR
    Investment Managers
    Finance

    KKR Leads Financing for Harvest Partners' Growth Investment in Med-Metrix

    KKR, a leading global investment firm, today announced that credit funds and accounts managed by KKR served as lead investors on a financing to support the growth investment from funds managed by Harvest Partners, LP ("Harvest") in Med-Metrix, LLC ("Med-Metrix" or "the Company"), a leading provider of technology-enabled Revenue Cycle Management ("RCM") solutions. KKR Capital Markets also served as Left Lead Arranger and Bookrunner on the transaction. The Company's management team, led by CEO Joseph Davi, will continue to lead Med-Metrix and remain significant owners of the business. Med-Metrix's prior owner, A&M Capital ("AMC"), will retain a minority stake in the Company and invest addit

    8/8/25 7:00:00 AM ET
    $KKR
    Investment Managers
    Finance

    FS KKR Capital Corp. Announces Second Quarter 2025 Results

    Declares Third Quarter 2025 Distribution of $0.70 per share PHILADELPHIA and NEW YORK, Aug. 6, 2025 /PRNewswire/ -- FS KKR Capital Corp. (NYSE:FSK), or the Company, today announced its financial and operating results for the quarter ended June 30, 2025, and that its board of directors has declared a third quarter 2025 distribution of $0.70 per share. Financial and Operating Highlights for the Quarter Ended June 30, 2025(1) Net investment income of $0.62 per share, compared to $0.67 per share for the quarter ended March 31, 2025Adjusted net investment income(2) of $0.60 per sha

    8/6/25 4:15:00 PM ET
    $FSK
    $KKR
    Investment Managers
    Finance

    $HSIC
    $KKR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Daniel William K bought $670,800 worth of shares (10,000 units at $67.08) (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    8/11/25 4:26:33 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Director Barakett Timothy R bought $4,127,319 worth of shares (35,000 units at $117.92) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    5/27/25 8:01:38 PM ET
    $KKR
    Investment Managers
    Finance

    Director Scully Robert W bought $1,503,733 worth of shares (13,250 units at $113.49) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    5/8/25 7:01:53 PM ET
    $KKR
    Investment Managers
    Finance

    $HSIC
    $KKR
    Financials

    Live finance-specific insights

    View All

    FS KKR Capital Corp. Announces Second Quarter 2025 Results

    Declares Third Quarter 2025 Distribution of $0.70 per share PHILADELPHIA and NEW YORK, Aug. 6, 2025 /PRNewswire/ -- FS KKR Capital Corp. (NYSE:FSK), or the Company, today announced its financial and operating results for the quarter ended June 30, 2025, and that its board of directors has declared a third quarter 2025 distribution of $0.70 per share. Financial and Operating Highlights for the Quarter Ended June 30, 2025(1) Net investment income of $0.62 per share, compared to $0.67 per share for the quarter ended March 31, 2025Adjusted net investment income(2) of $0.60 per sha

    8/6/25 4:15:00 PM ET
    $FSK
    $KKR
    Investment Managers
    Finance

    Henry Schein Reports Second Quarter 2025 Financial Results

    Second-quarter 2025 GAAP diluted EPS of $0.70, compared to $0.80 GAAP diluted EPS in the second quarter of 2024 Second-quarter 2025 non-GAAP diluted EPS of $1.10, compared to $1.23 non-GAAP diluted EPS in the second quarter of 2024 Maintains guidance for 2025 non-GAAP diluted EPS of $4.80 to $4.94, mid-single digit 2025 Adjusted EBITDA growth, and sales growth of 2% to 4% Takes next steps in collaboration with KKR to pursue additional opportunities to create shareholder value Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the second quarter ended June

    8/5/25 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    KKR & Co. Inc. Reports Second Quarter 2025 Results

    KKR & Co. Inc. (NYSE:KKR) today reported its second quarter 2025 results, which have been posted to the Investor Center section of KKR's website at https://ir.kkr.com/events-presentations/. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250731323085/en/ A conference call to discuss KKR's financial results will be held today, Thursday, July 31, 2025 at 9:00 a.m. ET. The conference call may be accessed by dialing (877) 407-0312 (U.S. callers) or +1 (201) 389-0899 (non-U.S. callers); a pass code is not required. Additionally, the conference call will be broadcast live over the Internet and may be accessed through the Investor Cente

    7/31/25 6:50:00 AM ET
    $KKR
    Investment Managers
    Finance

    $HSIC
    $KKR
    Leadership Updates

    Live Leadership Updates

    View All

    Harley-Davidson Announces Strategic Partnership with KKR and PIMCO

    Unlocks ~$1.25 billion of discretionary cash for Harley-Davidson and transforms Harley-Davidson Financial Services (HDFS) into a capital-light and derisked business that will continue to originate and service both new and existing retail loans Transaction monetizes HDFS through sale of 4.9% common equity interests to each partner and includes the sale of more than $5 billion of retail loan receivables at a premium to par HDFS has agreed to sell approximately two-thirds of retail loans originated by HDFS annually for a minimum period of five years Values HDFS at ~1.75x price to post-transaction book value and reinforces strategic and financial value of HDFS to Harley-Davidson customers, dea

    7/30/25 7:00:00 AM ET
    $HOG
    $KKR
    Motor Vehicles
    Consumer Discretionary
    Investment Managers
    Finance

    Stanley M. Bergman to Retire as Henry Schein's Chief Executive Officer at the End of 2025

    Mr. Bergman to Continue to Serve as Chairman of the Board Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that Stanley M. Bergman will retire as Chief Executive Officer (CEO) at the end of the year after 45 years at the Company, including more than 35 years as CEO. Mr. Bergman will continue to lead Henry Schein in his current role until his retirement and will remain as Chairman thereafter. The Board is commencing a formal search process in conjunction with a nationally recognized executive search firm and will consider internal and external candidates. "With the progress made advan

    7/15/25 7:05:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Announces Completion of Strategic Investment by KKR and Appointment of Dan Daniel to Board of Directors

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced the successful completion of a $250 million strategic investment by funds affiliated with KKR, a leading global investment firm. Upon the closing of this transaction, KKR has become the holder of approximately 12% of the common shares of Henry Schein. In connection with the investment, William K. "Dan" Daniel, Executive Advisor to KKR and former Executive Vice President of Danaher Corporation, has officially joined Henry Schein's Board of Directors as an independent director. He joins Max Lin, Partner at KKR and leader of the firm's Healt

    5/16/25 4:10:00 PM ET
    $HSIC
    $KKR
    Medical Specialities
    Health Care
    Investment Managers
    Finance

    $HSIC
    $KKR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Henry Schein Inc.

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    11/13/24 3:30:01 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by KKR & Co. Inc.

    SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)

    11/12/24 3:50:17 PM ET
    $KKR
    Investment Managers
    Finance

    SEC Form SC 13G filed by Henry Schein Inc.

    SC 13G - HENRY SCHEIN INC (0001000228) (Subject)

    11/12/24 9:32:27 AM ET
    $HSIC
    Medical Specialities
    Health Care